drugset / Trial / NCT03081052

Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

NCT03081052

Phase 4 Completed 519 enrolled Duke University
RandomizedParallel-groupTriple-blindOther

Summary

1\. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri®, iEPO) and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to conduct a cost-capture analysis on the expense each drug incurs per patient.

Timeline

Start
2017-05-04
Primary completion
2020-10-05
Completion
2021-09-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitric Oxide Other / unclassified Inhaled
Comparator epoprostenol Other / unclassified Inhaled

Indications

No indication recorded.